invIOs

invIOs stands for innovative immuno-oncology. We are a privately held biotech company based in Vienna, Austria, focused on the discovery and development of innovative cancer immunotherapies.     

Our projects:  

• The small molecule program INV501, a first-in-class small molecule activating the immune system only in an antigen-specific context. INV501 shows strong inhibition of tumor growth with 100% response rate and survival rates of up to 90% in rodent tumor models. INV501 data show immunological memory and long-term protection beyond end of treatment. In addition, INV501 has a synergistic effect with checkpoint inhibitors and prolongs CAR T cell cytotoxicity.
• Our pipeline also includes a clinically validated proprietary cell therapy platform (EPiC). EPiC radically shortens treatment times to approximately 6 hours enabling treatment in an out-patient setting using their fresh immune cells. We have several projects based on EPiC.   
• INV441 is a cell therapy using the EPiC platform in late preclinical stage to activate tumor cell killing via tumor infiltrating lymphocytes (TILs) for treatment of glioblastoma. First-in-human study is planned 2025 in collaboration with the Dana-Farber Cancer Institute, Boston, Mass.  
• Also, in our long-term development plan is INV451 - in discovery stage, this is a multiplex approach combining CAR-PBMCs and checkpoint inhibition using EPiC.